Post

New research · Ophthalmology
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 4d
Cohort studyGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026

Sub-Tenon's triamcinolone bridging to adalimumab therapy in refractory noninfectious uveitic macular edema.

Yaru Zou, Mingming Yang, Jing Zhang … Koju Kamoi
Read paper
OphthalmologyCohort study

Adding a steroid injection to adalimumab was linked to faster improvement in uveitic macular edema.

Sub-Tenon's triamcinolone bridging to adalimumab therapy in refractory noninfectious uveitic macular edema.

Yaru Zou … Koju Kamoi
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
Background

Noninfectious uveitic macular edema (uveitic macular edema) is a major cause of visual impairment and remains challenging in refractory cases.

Purpose

This study compared adalimumab monotherapy with adalimumab combined with sub-Tenon's triamcinolone acetonide (STTA) bridging therapy in refractory noninfectious uveitic macular edema.

Methods

In this retrospective longitudinal cohort study, 30 patients (44 eyes) with refractory noninfectious uveitic macular edema treated with adalimumab (2015-2025) were included.

n = 44 eyes
Results

adding the steroid shot sped up eye swelling improvement compared with adalimumab alone

HR by subgroup · 95% CI
null = 1
shorter time to improvement
2.85
did not differ significantly
0.71
More results

Adjusted analyses showed greater visual improvement in the bridging group at 12 months (difference 0.307 LogMAR; p < 0.001) and at 15, 24, and 36 months (p < 0.05).

Greater central subfield thickness reductions were observed at 3, 18, 21, and 36 months (p < 0.05).

More results

Relapse risk did not differ significantly (HR 0.711, 95% CI 0.155-3.272; p = 0.662).

IOP changes were generally comparable.

“
Conclusion

Adalimumab combined with STTA bridging therapy was associated with earlier anatomical improvement and additional visual benefits compared with adalimumab monotherapy, without increased relapse risk.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment